Lissner R, Schmidit H, Karch H
Biotest Pharma GmbH, Dreieich, Germany.
Infection. 1996 Sep-Oct;24(5):378-83. doi: 10.1007/BF01716084.
Enterohemorrhagic Escherichia coli (EHEC) causes a variety of clinical conditions, the most important being hemorrhagic colitis and hemolytic uremic syndrome. A curative therapy of EHEC diseases is not yet feasible. This study investigates the antibody reactivity of Lactobin, a standardized immunoglobulin (Ig) preparation, obtained from the colostra of non-immunized cows. Three different batches of Lactobin exhibited equally high titers of specific antibodies against Shiga-like toxins (SLTs, verocytotoxins) and EHEC hemolysin (EHEC-Hly) produced by E. coli O157. In addition, Lactobin blocked the cytotoxic effect of SLT-I and SLT-II on Vero cell monolayers and inhibited the cytolytic effects of EHEC-Hly on human erythrocytes. Since Lactobin contains high levels of antibodies and neutralizing activity against important virulence factors of EHEC O157, this drug has potential use in the treatment of diarrhea and the prevention of EHEC-associated hemolytic uremic syndrome.
肠出血性大肠杆菌(EHEC)可引发多种临床病症,其中最重要的是出血性结肠炎和溶血性尿毒症综合征。目前尚无针对EHEC疾病的治愈性疗法。本研究调查了Lactobin的抗体反应性,Lactobin是一种标准化免疫球蛋白(Ig)制剂,取自未免疫奶牛的初乳。三批不同的Lactobin对大肠杆菌O157产生的志贺样毒素(SLTs,即Vero细胞毒素)和EHEC溶血素(EHEC-Hly)均表现出同样高滴度的特异性抗体。此外,Lactobin可阻断SLT-I和SLT-II对Vero细胞单层的细胞毒性作用,并抑制EHEC-Hly对人红细胞的溶细胞作用。由于Lactobin含有高水平的抗体以及针对EHEC O157重要毒力因子的中和活性,这种药物在治疗腹泻和预防EHEC相关的溶血性尿毒症综合征方面具有潜在用途。